Celldex falls about 2% as phase 2 barzolvolimab trial misses atopic dermatitis endpoints
FROM THE WIRE · SEEKINGALPHA.COM
Celldex shares fall about 2% after its phase 2 barzolvolimab trial misses atopic dermatitis endpoints. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA phase 2 trial miss is relevant for the stock and expectations for the drug.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Celldex shares fall about 2%.
- 02The phase 2 barzolvolimab trial misses atopic dermatitis endpoints.
- 03The company abandons the atopic dermatitis program.